drugset
drugset / Trial / NCT04215965

Efficacy and Safety of a Citrate-based Anticoagulation With Calcium-free Phosphate-containing Fluid in Renal Replacement Therapy

NCT04215965 ↗

Phase 4 Unknown 100 enrolled Assistance Publique Hopitaux De Marseille
RandomizedParallel-groupSingle-blindTreatment

Summary

In the present prospective multicenter RCT we will evaluate the effects on efficacy, acid-base status and serum phosphate levels of a new RCA protocol for Continuous Venovenous Hemodiafiltration (CVVHDF) using an 18 mmol/l citrate solution in combination with a calcium-free phosphate-containing solution, acting as dialysate and replacement fluid. The new protocol will be introduced with the following targets: a) to refine buffers balance of a previously adopted RCA protocol for Continuous Venovenous Hemofiltration (CVVH), based on a 18 mmol/l citrate solution (Regiocit) combined with calcium and phosphate-free dialysate fluid (PrismOcal B22) and a conventional phosphate-containing replacement fluid (Phoxilium) to prevent CRRT-related phosphate depletion

Timeline

Start
2020-05-02
Primary completion
2021-08-01
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Biphozyl Unknown — —
Comparator Phoxilium Unknown — —
Comparator Prismocal B22 Unknown — —

Indications

No indication recorded.